GHRP-2 (Pralmorelin)
Worth trying, BioHarmony verdict
BioHarmony score 5.8 out of 10
GHRP-2 (pralmorelin) is a ghrelin-receptor peptide that drives a strong growth-hormone pulse, approved in Japan since 2004 as a diagnostic test. It is a stronger releaser than ipamorelin but less selective, raising cortisol, prolactin, and appetite by about 36 percent per Laferrere 2005, with no human body-composition outcome trials.
Read full reportWhat is GHRP-2 (Pralmorelin)?
GHRP-2, also called pralmorelin or KP-102, is a lab-made peptide that tells your pituitary to fire off a strong, fast pulse of your own growth hormone. It does this by binding the ghrelin receptor, the same receptor your gut's hunger hormone uses, which is why it both releases growth hormone and makes you hungry. It is a stronger releaser than ipamorelin, and that strength is the whole pitch. A single dose drives a peak growth-hormone response well above an equal dose of GHRH, per Tiulpakov 1995, and continuous dosing keeps growth hormone and IGF-1 elevated for weeks, per Bowers 2004. It lands at Neutral because that real power comes with real baggage.
From the BioHarmony report, reviewed Sep 8, 2026.
Saved on this device only.
How it is thought to work
Amplifies your own pulsatile growth-hormone release and opposes somatostatin
Safety watch-outs
- Rising fasting glucose or HbA1c: stop and consult a clinician, especially with diabetes or prediabetes.
- New or worsening numbness or tingling, a possible fluid-related nerve compression: reduce dose or stop.
- Any active or suspected cancer: do not use, since growth-hormone and IGF-1 stimulation is contraindicated.
- Signs of high prolactin such as low libido or menstrual changes on chronic use: stop and reassess.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
No approved-label or study protocol is recorded for GHRP-2 (Pralmorelin) yet.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
- International Peptide Society 2018 Compound Curriculum Dr. William Seeds,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA places injectable and nasal GHRP-2 in 503B Category 2 and identifies immunogenicity, impurity, and serious adverse-event concerns.
Primary sources
- Certain bulk drug substances for use in compounding that may present significant safety risks U.S. Food and Drug Administration,
Related peptides for recovery & tissue repair
- 7.4Thymosin Alpha-1Thymosin Alpha-1 is a 28-amino-acid thymic peptide with strongest evidence in immune-compromised and hospital-adjacent settings: Cao 2024 pooled 39 acute COPD…
- 7.2GHK-Cu (Copper Peptide)GHK-Cu is a human copper-binding tripeptide with the best evidence for topical skin repair and wound healing, including Mulder 1994 diabetic ulcer data showing 98.5%…
- 7.1SemaxSemax is a Russian-developed ACTH 4-7 + PGP heptapeptide with the strongest human signal in post-stroke recovery, including a 110-patient Gusev et al.
- 6.9Thymosin Beta-4 (Full)Thymosin beta-4 is the native 43-amino-acid peptide that promotes tissue repair via actin-sequestering and the Ac-SDKP repair axis.
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.